Biologics arm of 3SBio making monoclonal antibodies and biosimilars for autoimmune disease and oncology.
Biologics arm of 3SBio making monoclonal antibodies and biosimilars for autoimmune disease and oncology.
In one line: A China biosimilar unit akin to a small Amgen biosimilars arm.
Moat: narrow (process know-how, IP / patents). In-house antibody manufacturing and an affiliate relationship with parent 3SBio's commercial network.
Headquarters: Shenyang, China · Founded: 2002 · Employees: 1,012
Size Sunshine Guojian Pharmaceutical (Shanghai) (688336.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.81B, the 632nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥28.25 on 18 Nov 2026.
Performance Over six months the shares fell 38.5%, against +3.5% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 19 in its peer set.
Growth Revenue grew 227.2% over the last twelve months (peer median +8.4%); the operating margin is 73.8% (peer median 15.7%).
Valuation It trades at 39.9× forward earnings against a peer median of 18.5× (4th most expensive of 13).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +45%, so the hurdle is -44 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 23.7 points above its cost of capital (9.5% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.48B | CN¥4.20B | CN¥1.19B | CN¥1.01B | CN¥823M |
| Revenue growth | — | +253% | +18% | +23% | — |
| Gross profit | CN¥4.19B | CN¥3.82B | CN¥836M | CN¥743M | CN¥564M |
| EBITDA | n/a | CN¥3.24B | CN¥335M | CN¥287M | CN¥85.0M |
| Net income | CN¥3.09B | CN¥2.90B | CN¥705M | CN¥295M | CN¥49.3M |
| Free cash flow | CN¥181M | CN¥2.94B | CN¥484M | CN¥203M | CN¥42.3M |
| Capital expenditure | CN¥276M | CN¥253M | CN¥281M | CN¥236M | CN¥221M |
| Total debt | CN¥0 | CN¥0 | CN¥50.0M | CN¥50.0M | CN¥150M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | $3.81B | -38% | +227% | 74% | 39.9× | 0.9% |
| 3SBio 1530.HK | $4.28B | -31% | +102% | 61% | 12.0× | n/a |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 52.3× | 11.6% |
| Bio-Thera Solutions 688177.SS | $929M | -23% | +24% | -44% | n/a | n/a |
| Shanghai Henlius Biotech 2696.HK | $3.05B | -39% | +33% | 12% | 21.3× | 14.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688336.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.5% | +2.6% | 2nd lowest of 21 |
| 6-month return | -38.5% | +3.5% | lowest of 19 |
| Distance from 52-week high | -57.6% | -26.4% | 2nd lowest of 21 |
| Revenue growth (TTM) | +227.2% | +8.4% | highest of 18 |
| Operating margin | 73.8% | 15.7% | highest of 17 |
| Forward P/E | 39.9× | 18.5× | 4th most expensive of 13 |
| Growth the price implies (Req g, 7 yrs) | 0.9% | 5.5% | 5th least demanding of 13 |
| Growth delivered (Del g) | +45.1% | +5.0% | 3rd highest of 13 |
| Hurdle (Req g minus delivered) | -44.2 pp | -5.6 pp | 3rd least demanding of 13 |
| ROIC minus cost of capital | +23.7 pp | +4.3 pp | highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $3.81B | -38% | +227% | 74% | 39.9× | 0.9% | +45.1% |
| Livzon Pharmaceutical 000513.SZ | China | $3.76B | +4% | -14% | 19% | 16.9× | -9.6% | +2.7% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $3.75B | -10% | -13% | 20% | 28.5× | 16.2% | -5.8% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.75B | +12% | +14% | 20% | 21.9× | 1.2% | +12.1% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | n/a | 34.7% | +159.5% |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Novast Laboratories 301569.SZ | China | $3.92B | n/a | +3% | 27% | n/a | 57.4% | +3.1% |
| HanmiPharm 128940.KS | South Korea | $3.95B | -2% | +14% | 16% | 15.0× | 4.7% | +7.5% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% | -1.0% |
| Definium Therapeutics DFTX | United States | $3.99B | +40% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% | +5.9% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% | +7.8% |
| Yuhan 000100.KS | South Korea | $4.11B | -10% | +8% | 6% | 40.4× | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | n/a | 58.0% | +4.2% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 16.8× | n/a | n/a |
| Santen Pharmaceutical 4536.T | Japan | $4.14B | +10% | +2% | 16% | 16.7× | -5.0% | +3.2% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 63.6× | n/a | n/a |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $3.49B | -38% | +36% | -14% | n/a | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% | +367.3% |